Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT ID: NCT04882163
Last Updated: 2021-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2021-10-10
2029-04-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
NCT04884035
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04790903
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03533283
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
NCT04464798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CC-220 + Polatuzumab vedotin + rituximab- Cohort A
Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
CC-220
CC-220
Polatuzumab vedotin
Polatuzumab vedotin
Rituximab
Rituximab
CC-220 + Tafasitamab- Cohort B
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
CC-220
CC-220
Tafasitamab
Tafasitamab
CC-220 + Rituximab + Chemo (Cohort C)
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
CC-220
CC-220
Rituximab
Rituximab
Gemcitabine
Gemcitabine
Cisplatin
Cisplatin
Dexamethasone
Dexamethasone
CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)
Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
CC-220
CC-220
Polatuzumab vedotin
Polatuzumab vedotin
Rituximab
Rituximab
Bendamustine
Bendamustine
CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E
Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
CC-220
CC-220
Tafasitamab
Tafasitamab
Lenalidomide
Lenalidomide
CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)
Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
CC-220
CC-220
Rituximab
Rituximab
Gemcitabine
Gemcitabine
Cisplatin
Cisplatin
Dexamethasone
Dexamethasone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-220
CC-220
Polatuzumab vedotin
Polatuzumab vedotin
Rituximab
Rituximab
Tafasitamab
Tafasitamab
Gemcitabine
Gemcitabine
Cisplatin
Cisplatin
Dexamethasone
Dexamethasone
Bendamustine
Bendamustine
Lenalidomide
Lenalidomide
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participant is ≥ 18 years of age at the time of signing the informed consent form (ICF).
2. Participant has histologically confirmed (per local evaluation) diagnosis of, aggressive B-cell lymphoma (a-BCL) according to 2016 WHO classification among the following subtypes:
1. Diffuse large B-cell lymphoma (DLBCL), Not otherwise specified (NOS) including Germinal center B-cell and Activated B-cell types;
2. High-grade B-cell lymphoma, with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements;
3. Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);
4. Primary cutaneous DLBCL-leg type;
5. Anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma;
6. Epstein Barr virus positive (EBV+) DLBCL, NOS;
7. Grade 3b Follicular lymphoma (FL).
3. Participants must have relapsed or refractory disease after at least 2 prior lines of therapy including Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP)-like regimen OR after one prior line of standard therapy and being not eligible for autologous stem cell transplant (ASCT); participants previously treated with CAR-T therapy can be enrolled.
4. Participant must have measurable disease defined by at least one FDG-avid lesion for FDGavid-subtype and one bi-dimensionally measurable (\> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).
5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
6. Participant must have the following laboratory values:
1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L in case of documented bone marrow involvement (\> 50% or tumor cells), without growth factor support for 7 days (14 days if pegylated granulocyte-colony stimulating factor (peg-G-CSF))
2. Hemoglobin ≥ 8 g/dL
3. Platelets ≥ 75 x 109/L or ≥ 50 x 109/L in case of documented bone marrow involvement (\> 50% or tumor cells), without transfusion for 7 days
4. Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 2.5 x ULN except in the case of documented liver involvement by lymphoma, where ALT/SGPT and AST/SGOT must be ≤ 5.0 x ULN.
5. Serum total bilirubin ≤ 2.0 mg/dL (34 μmol/L) except in cases of Gilbert syndrome, then ≤ 5.0 mg/dL (86 μmol/L)
6. Estimated serum creatinine clearance of ≥ 50 mL/minute using the modification of diet in renal disease formula.
7. All participants must:
1. Have an understanding that the study drug could have a potential teratogenic risk.
2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 Pregnancy Prevention Plan for Participants in Clinical Trials.
8. A female of childbearing potential (FCBP) must:
a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy.
9. Male participants must:
1. Practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.
Exclusion Criteria
1. Participant has any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
a. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved
2. Participant has any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.
3. Participant has any other subtype of lymphoma.
4. Participant has received systemic anti-cancer treatment, CAR-T or any T-cell targeting treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-220, whichever is shorter.
5. Participant has received prior therapy with a Cereblon-modulating drug (eg, lenalidomide, avadomide) ≤ 4 weeks prior to starting CC-220.
6. Participant has persistent diarrhea or malabsorption ≥ Grade 2 (NCI-CTCAE v5.0), despite medical management.
7. Participant has peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).
8. Participant is on chronic systemic immunosuppressive therapy or corticosteroids.
9. Participant has impaired cardiac function or clinically significant cardiac disease.
10. Participant had major surgery ≤ 2 weeks prior to starting CC-220.
11. Participant has known seropositivity for or active viral infection with human immunodeficiency virus (HIV).
12. Participant has known chronic active hepatitis B
13. Participant has history of other malignancy, unless being free of the disease for ≥ 3 years prior to starting study drug; exceptions to the ≥ 3-year time limit include history of the following:
1. Localized non-melanoma skin cancer
2. Carcinoma in situ of the cervix
3. Carcinoma in situ of the breast
4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis \[TNM\] staging system) or prostate cancer that has been treated with curative intent.
14. Participant has current treatment with strong CYP3A4/5 modulators.
15. Participant has known hypersensitivity to any component of planned combination medications in the regimen.
16. Participant has known allergy to thalidomide, pomalidomide, lenalidomide or avadomide.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Medizinische Universität Graz
Graz, , Austria
Universitätsklinikum St. Pölten
Sankt Pölten, , Austria
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
Hôpital de Jolimont
La Louvière, , Belgium
H.-Hartziekenhuis Roeselare-Menen vzw
Roeselare, , Belgium
EDOG - Institut Bergonie - PPDS
Bordeaux, , France
Hôpital François Mitterand
Dijon, , France
Centre Hospitalier Lyon Sud
Lyon, , France
EDOG - Institut Claudius Regaud - PPDS
Toulouse, , France
Gustave Roussy
Villejuif, , France
Samsung Medical Center
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Hospital Universitario Germans Trias i Pujol
Badalona, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Complejo Asistencial Universitario de Salamanca - H. Clinico
Salamanca, , Spain
Hospital Universitario Virgen del Rocio - PPDS
Seville, , Spain
Taipei Veterans General Hospital
Beitou District, Taipei City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Taiwan University Hospital
Taipei, Zhongzheng Dist., , Taiwan
Beatson West of Scotland Cancer Centre
Glasgow Scotland, , United Kingdom
Royal Liverpool University Hospital
Liverpool, , United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, , United Kingdom
University Hospital Southampton NHS Foundation Trust - Southampton General Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-005333-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CC-220-DLBCL-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.